GlassScriptPhysician profile
James L Delgadillo
NPI 1619258019
$2,288.04
in general payments reported to CMS, 2019-2025
26 companies · $656 in 2025
The $656 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $194 · 2020: $566 · 2021: $638 · 2023: $32.52 · 2024: $202 · 2025: $656.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $890.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $890.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $542.33 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $340.91 | 2020-2025 | |
| Lilly USA, LLC | $318.28 | 2019-2025 | Jardiance, Mounjaro |
| Janssen Pharmaceuticals, INC | $143.31 | 2020-2021 | |
| Phathom Pharmaceuticals, INC. | $100.19 | 2024-2025 | Voquezna |
| Novo Nordisk INC | $97.83 | 2021-2025 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $71.07 | 2020-2025 | Trelegy Ellipta |
| Amarin Pharma, INC. | $63.43 | 2020-2021 | |
| Esperion Therapeutics, INC. | $60.97 | 2021-2025 | Nexletol |
| Allergan, INC. | $57.04 | 2020 | |
| Supernus Pharmaceuticals, INC. | $55.35 | 2020 | |
| Amgen INC. | $52.03 | 2021-2025 | Otezla, Repatha, Repatha |
| Daiichi Sankyo INC. | $42.83 | 2021 | |
| Pfizer INC. | $42.42 | 2020-2021 | |
| Gilead Sciences, INC. | $40.54 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $38.64 | 2021 | |
| Xeris Pharmaceuticals, INC. | $35.48 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.93 | 2020-2021 | |
| Astellas Pharma US INC | $25.00 | 2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.54 | 2021 | |
| Mylan Specialty L.P. | $20.94 | 2021 | |
| Medtronic, INC. | $19.18 | 2024 | Kyphon Express II Kyphopak Tray |
| Teva Pharmaceuticals USA, INC. | $17.14 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.83 | 2024 | |
| Exact Sciences Corporation | $16.06 | 2023 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $13.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Delgadillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.